In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 650 ( 2022-06-22)
Abstract:
Nonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation. They validated the risk signatures in independent cohorts and additionally found that one signature was altered in patients undergoing different therapeutic treatments.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo4474
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Bookmarklink